Abstract:Congenital disorders of glycosylation (CDG) are a group of rare monogenic human disorders caused by defects in the genes encoding the proteins that generate, attach, and modify glycans, thus disrupting cellular glycosylation machinery. Over 200 CDG caused by disruptions of 189 different genes are currently known. The multi-system disease manifestations of the CDG disorders highlight the importance of glycosylation across the organ systems. Clinical manifestations of CDG tend to group among genes contributing to the same glycosylation pathways, suggesting shared pathophysiology related to the glycosylation disruptions. However, the underlying glycosylation disruptions and pathophysiologic mechanisms responsible for specific CDG clinical manifestations have been determined for only a few hypoglycosylated proteins. The Frontiers in CDG Consortium (FCDGC) is an international network of clinical sites, laboratories, and patient advocacy groups established in 2019 to improve clinical symptoms, quality of life, and life expectancy for individuals with CDG. FCDGC seeks to answer decades of unresolved questions, address knowledge gaps, develop and validate new biochemical diagnostic techniques and therapeutic biomarkers, and explore novel therapeutic options for CDG. Over the past 5 years, FCDGC has launched a Natural History Study with over 300 CDG patients, discovered novel biomarkers suggesting new mechanisms of disease, and launched clinical trials aiming to restore appropriate glycosylation and targeting newly identified potential mechanisms of disease. Technical advances in glycobiology are making it increasingly possible to comprehensively catalog glycoproteomic data and to probe functional impact of altered glycosylation. My laboratory applies glycoproteomic technologies to samples from human subjects and genetic model systems to identify glycosylation abnormalities and unlock new insights from translational glycobiology. Current findings and accomplishments highlight the ongoing bottlenecks and knowledge gaps at intersections of glycobiology and clinical care requiring further investigation.

Metabolism, Cell Surface Organization, and Disease

O-GlcNAcylation, a Sweet Link to the Pathology of Diseases

N-Glycosylation as a Modulator of Protein Conformation and Assembly in Disease

Genetics of glycosylation in mammalian development and disease

Vertebrate protein glycosylation: diversity, synthesis and function

Glycosylation: mechanisms, biological functions and clinical implications

A little sugar goes a long way: The cell biology of O-GlcNAc

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases

Sugary Logistics Gone Wrong: Membrane Trafficking and Congenital Disorders of Glycosylation

Spatiotemporal diversity and regulation of glycosaminoglycans in cell homeostasis and human disease

Deciphering the cell surface sugar‐coating via Biochemical Pathways

Metabolic Regulation of Cell Fate and Function.

Global view of human protein glycosylation pathways and functions

O‐GlcNAcylation: cellular physiology and therapeutic target for human diseases

The post-translational modification O-GlcNAc is a sensor and regulator of metabolism

Protein structure, a genetic encoding for glycosylation

O -GlcNAcylation is a key regulator of multiple cellular metabolic pathways

Protein glycosylation. Structural and functional aspects

The Effects of N-Linked Glycosylation on SLC6 Transporters

Reading and Writing the Human Glycocode